← Back to Search

Remote Assessment Technology for Multiple Sclerosis

Phase 2
Waitlist Available
Research Sponsored by Transparency Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females between the ages of 18 and 64
Baseline score of 0-5.5 on Kurtzke's Expanded Disability Status Scale (EDSS)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 6
Awards & highlights

Study Summary

This trial is testing whether the MSFC can be done at home using video conferencing technology.

Who is the study for?
Adults aged 18-64 with a documented diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) and an EDSS score between 0-5.5 can join this trial. They must have normal blood pressure, not be too low or high, and someone at home to help during tests. People with very low/high blood pressure or slow heart rate (<50 bpm) cannot participate.Check my eligibility
What is being tested?
The study is testing the use of the Multiple Sclerosis Functional Composite (MSFC), both at a study site and remotely from home using technology like video calls. This is to prepare for a future phase 2 trial evaluating lisinopril in treating multiple sclerosis.See study design
What are the potential side effects?
Since this stage of the trial focuses on calibrating assessment tools rather than medication effects, specific side effects are not detailed here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 64 years old.
Select...
My disability level is moderate, as measured by a specific scale.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
MSFC Score Comparison
Mobile 9-hole Peg Test Time Comparison
Mobile Paced Auditory Serial Addition Test Score Comparison
+2 more

Trial Design

2Treatment groups
Active Control
Group I: Group 2Active Control2 Interventions
Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
Group II: Group 1Active Control2 Interventions
Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.

Find a Location

Who is running the clinical trial?

Transparency Life SciencesLead Sponsor
1 Previous Clinical Trials
51 Total Patients Enrolled
Tomasz Sablinski, MD, PhDStudy DirectorTransparency Life Sciences
2 Previous Clinical Trials
312 Total Patients Enrolled

Media Library

Multiple Sclerosis Functional Composite Clinical Trial Eligibility Overview. Trial Name: NCT02369926 — Phase 2
Multiple Sclerosis Research Study Groups: Group 2, Group 1
Multiple Sclerosis Clinical Trial 2023: Multiple Sclerosis Functional Composite Highlights & Side Effects. Trial Name: NCT02369926 — Phase 2
Multiple Sclerosis Functional Composite 2023 Treatment Timeline for Medical Study. Trial Name: NCT02369926 — Phase 2
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top